Management of Localized Breast Angiosarcoma by North American Radiation and Medical Oncologists

Jess Hatfield, Shearwood McClelland, Jia Luo, Catherine Degnin, Yiyi Chen, Ronald Maggiore, Timur Mitin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Primary breast angiosarcoma is a rare malignancy with no clinical trials to guide management. The current use of surgery, chemotherapy, and radiotherapy among North American oncologists is unknown. Patients and Methods: An institutional review board–approved anonymous electronic survey was distributed to 9660 practicing North American radiation and medical oncologists. Questions pertained to treatment recommendations for localized nonmetastatic primary breast angiosarcoma, as well as knowledge/use of β-blockers in angiosarcoma. The Fisher exact test was used to compare responses of medical and radiation oncologists. Results: Surgery was recommended by 95% of all respondents. Chemotherapy was recommended by over half of medical and radiation oncologists. Radiotherapy was recommended by 92% of radiation and 56% of medical oncologists. The most common treatment recommendation was a trimodal treatment, with up-front surgery followed by adjuvant chemotherapy, then by adjuvant radiotherapy. Twenty-two percent of respondents were aware of clinical data pertaining to the use of β-blockers in management of angiosarcoma, and among these respondents 69% were comfortable incorporating this treatment into standard practice. Conclusion: Trimodal management of primary localized breast angiosarcoma is supported by North American radiation and medical oncologists, with the majority recommending up-front surgery followed by adjuvant chemotherapy and radiation. The recently published reports of successful use of β-blockers are not yet known among North American clinicians, but there is a great enthusiasm to incorporate these commonly prescribed medications into standard practice. These findings may greatly influence the standard of care for breast angiosarcoma treatment, particularly given the absence of Level I–supported evidence. To study the current use of surgery, chemotherapy, and radiotherapy (trimodal management), we asked North American radiation and medical oncologists to fill out a questionnaire. Trimodal management of primary localized breast angiosarcoma is supported by these oncologists; most recommend surgery with adjuvant chemotherapy and radiation, with the usefulness of β-blockers remaining unknown. These findings may greatly influence the standard of care for breast angiosarcoma treatment.

Original languageEnglish (US)
JournalClinical Breast Cancer
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Adjuvant Chemotherapy
Hemangiosarcoma
Radiotherapy
Radiation
Standard of Care
Drug Therapy
Therapeutics
Adjuvant Radiotherapy
Radiation Oncologists
Angiosarcoma of the breast
Surveys and Questionnaires
Clinical Trials
Oncologists
Neoplasms

Keywords

  • Angiosarcoma
  • Breast cancer
  • Chemotherapy
  • Radiotherapy
  • β-Blocker use

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Management of Localized Breast Angiosarcoma by North American Radiation and Medical Oncologists. / Hatfield, Jess; McClelland, Shearwood; Luo, Jia; Degnin, Catherine; Chen, Yiyi; Maggiore, Ronald; Mitin, Timur.

In: Clinical Breast Cancer, 01.01.2018.

Research output: Contribution to journalArticle

Hatfield, Jess ; McClelland, Shearwood ; Luo, Jia ; Degnin, Catherine ; Chen, Yiyi ; Maggiore, Ronald ; Mitin, Timur. / Management of Localized Breast Angiosarcoma by North American Radiation and Medical Oncologists. In: Clinical Breast Cancer. 2018.
@article{ee84fe0072714a21abcbc6ea1be6465d,
title = "Management of Localized Breast Angiosarcoma by North American Radiation and Medical Oncologists",
abstract = "Introduction: Primary breast angiosarcoma is a rare malignancy with no clinical trials to guide management. The current use of surgery, chemotherapy, and radiotherapy among North American oncologists is unknown. Patients and Methods: An institutional review board–approved anonymous electronic survey was distributed to 9660 practicing North American radiation and medical oncologists. Questions pertained to treatment recommendations for localized nonmetastatic primary breast angiosarcoma, as well as knowledge/use of β-blockers in angiosarcoma. The Fisher exact test was used to compare responses of medical and radiation oncologists. Results: Surgery was recommended by 95{\%} of all respondents. Chemotherapy was recommended by over half of medical and radiation oncologists. Radiotherapy was recommended by 92{\%} of radiation and 56{\%} of medical oncologists. The most common treatment recommendation was a trimodal treatment, with up-front surgery followed by adjuvant chemotherapy, then by adjuvant radiotherapy. Twenty-two percent of respondents were aware of clinical data pertaining to the use of β-blockers in management of angiosarcoma, and among these respondents 69{\%} were comfortable incorporating this treatment into standard practice. Conclusion: Trimodal management of primary localized breast angiosarcoma is supported by North American radiation and medical oncologists, with the majority recommending up-front surgery followed by adjuvant chemotherapy and radiation. The recently published reports of successful use of β-blockers are not yet known among North American clinicians, but there is a great enthusiasm to incorporate these commonly prescribed medications into standard practice. These findings may greatly influence the standard of care for breast angiosarcoma treatment, particularly given the absence of Level I–supported evidence. To study the current use of surgery, chemotherapy, and radiotherapy (trimodal management), we asked North American radiation and medical oncologists to fill out a questionnaire. Trimodal management of primary localized breast angiosarcoma is supported by these oncologists; most recommend surgery with adjuvant chemotherapy and radiation, with the usefulness of β-blockers remaining unknown. These findings may greatly influence the standard of care for breast angiosarcoma treatment.",
keywords = "Angiosarcoma, Breast cancer, Chemotherapy, Radiotherapy, β-Blocker use",
author = "Jess Hatfield and Shearwood McClelland and Jia Luo and Catherine Degnin and Yiyi Chen and Ronald Maggiore and Timur Mitin",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.clbc.2018.09.009",
language = "English (US)",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",

}

TY - JOUR

T1 - Management of Localized Breast Angiosarcoma by North American Radiation and Medical Oncologists

AU - Hatfield, Jess

AU - McClelland, Shearwood

AU - Luo, Jia

AU - Degnin, Catherine

AU - Chen, Yiyi

AU - Maggiore, Ronald

AU - Mitin, Timur

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Introduction: Primary breast angiosarcoma is a rare malignancy with no clinical trials to guide management. The current use of surgery, chemotherapy, and radiotherapy among North American oncologists is unknown. Patients and Methods: An institutional review board–approved anonymous electronic survey was distributed to 9660 practicing North American radiation and medical oncologists. Questions pertained to treatment recommendations for localized nonmetastatic primary breast angiosarcoma, as well as knowledge/use of β-blockers in angiosarcoma. The Fisher exact test was used to compare responses of medical and radiation oncologists. Results: Surgery was recommended by 95% of all respondents. Chemotherapy was recommended by over half of medical and radiation oncologists. Radiotherapy was recommended by 92% of radiation and 56% of medical oncologists. The most common treatment recommendation was a trimodal treatment, with up-front surgery followed by adjuvant chemotherapy, then by adjuvant radiotherapy. Twenty-two percent of respondents were aware of clinical data pertaining to the use of β-blockers in management of angiosarcoma, and among these respondents 69% were comfortable incorporating this treatment into standard practice. Conclusion: Trimodal management of primary localized breast angiosarcoma is supported by North American radiation and medical oncologists, with the majority recommending up-front surgery followed by adjuvant chemotherapy and radiation. The recently published reports of successful use of β-blockers are not yet known among North American clinicians, but there is a great enthusiasm to incorporate these commonly prescribed medications into standard practice. These findings may greatly influence the standard of care for breast angiosarcoma treatment, particularly given the absence of Level I–supported evidence. To study the current use of surgery, chemotherapy, and radiotherapy (trimodal management), we asked North American radiation and medical oncologists to fill out a questionnaire. Trimodal management of primary localized breast angiosarcoma is supported by these oncologists; most recommend surgery with adjuvant chemotherapy and radiation, with the usefulness of β-blockers remaining unknown. These findings may greatly influence the standard of care for breast angiosarcoma treatment.

AB - Introduction: Primary breast angiosarcoma is a rare malignancy with no clinical trials to guide management. The current use of surgery, chemotherapy, and radiotherapy among North American oncologists is unknown. Patients and Methods: An institutional review board–approved anonymous electronic survey was distributed to 9660 practicing North American radiation and medical oncologists. Questions pertained to treatment recommendations for localized nonmetastatic primary breast angiosarcoma, as well as knowledge/use of β-blockers in angiosarcoma. The Fisher exact test was used to compare responses of medical and radiation oncologists. Results: Surgery was recommended by 95% of all respondents. Chemotherapy was recommended by over half of medical and radiation oncologists. Radiotherapy was recommended by 92% of radiation and 56% of medical oncologists. The most common treatment recommendation was a trimodal treatment, with up-front surgery followed by adjuvant chemotherapy, then by adjuvant radiotherapy. Twenty-two percent of respondents were aware of clinical data pertaining to the use of β-blockers in management of angiosarcoma, and among these respondents 69% were comfortable incorporating this treatment into standard practice. Conclusion: Trimodal management of primary localized breast angiosarcoma is supported by North American radiation and medical oncologists, with the majority recommending up-front surgery followed by adjuvant chemotherapy and radiation. The recently published reports of successful use of β-blockers are not yet known among North American clinicians, but there is a great enthusiasm to incorporate these commonly prescribed medications into standard practice. These findings may greatly influence the standard of care for breast angiosarcoma treatment, particularly given the absence of Level I–supported evidence. To study the current use of surgery, chemotherapy, and radiotherapy (trimodal management), we asked North American radiation and medical oncologists to fill out a questionnaire. Trimodal management of primary localized breast angiosarcoma is supported by these oncologists; most recommend surgery with adjuvant chemotherapy and radiation, with the usefulness of β-blockers remaining unknown. These findings may greatly influence the standard of care for breast angiosarcoma treatment.

KW - Angiosarcoma

KW - Breast cancer

KW - Chemotherapy

KW - Radiotherapy

KW - β-Blocker use

UR - http://www.scopus.com/inward/record.url?scp=85055466210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055466210&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2018.09.009

DO - 10.1016/j.clbc.2018.09.009

M3 - Article

C2 - 30482726

AN - SCOPUS:85055466210

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

ER -